Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

February 18, 2016

Primary Completion Date

January 18, 2017

Study Completion Date

April 27, 2017

Conditions
Obesity
Interventions
DRUG

Perindopril

Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks

Trial Locations (13)

4540-297

Unidade de Saúde Familiar Escariz, Arouca

3814-501

Centro Hospitalar do Baixo Vouga (CHBV), EPE, Aveiro

4410 - 273

Unidade de Saúde Familiar Canelas, Canelas

6200-251

Centro Hospitalar Cova da Beira (CHCB), EPE, Covilha

4990-145

Unidade de Saúde Familiar Lethes, Ponte de Lima

4200-319

Centro Hospitalar de São João (CHSJ), E.P.E, Porto

4200-510

Unidade de Saúde Familiar Arca d'Água, Porto

4250-113

Unidade de Cuidados de Saúde Personalizados Carvalhido, Porto

4901 - 858

Unidade Local de Saúde do Alto Minho (ULSAM), E.P.E., Viana do Castelo

4400-043

Unidade de Saúde Familiar Nova Salus, Vila Nova de Gaia

4400-230

Unidade de Saúde Familiar Santo André de Canidelo, Vila Nova de Gaia

4434-502

Centro Hospitalar V.N.Gaia/Espinho (CHVNG/E)- Endocrinology, Vila Nova de Gaia

Centro Hospitalar Vila Nova de Gaia/Espinho (CHVNG/E), Vila Nova de Gaia

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Blueclinical, Ltd.

OTHER

lead

Gene PreDiT

INDUSTRY

NCT02777489 - Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects | Biotech Hunter | Biotech Hunter